MarginsXMarginsX
Home › Markets › Health Care › ALNY

Alnylam Pharmaceuticals Inc. (ALNY)

ALNY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$159.73
-3.22% on the day
Market cap
$21.4B
Large cap
Revenue · 2025
$3.7B
+65.2% on 2024
Net income · 2025
$313.7M
8.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/0001628280-26-007497-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALNY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2004
SEC CIK0001178670
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$3.7B
Net income$313.7M
Operating income$501.6M
Net margin8.4%
Operating margin13.5%
Revenue growth+65.2%
Cash$1.7B
Total assets$5.0B
P/E (computed)68.2×
P/S (computed)5.8×

Warning signs

Cash runway
Cash-flow positive
$1.8B cash at September 30, 2026
Share count, 1 year
+1.4%
2025-10-24 to 2026-10-23 · +6.7% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$50.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$1.8B cash; operating cash flow $245.8M a quarter.Report 2026-09-30
Shares outstanding133,937,576 (2026-10-23); 132,113,818 a year earlier; 125,492,927 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-02-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $50.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.5B$2.2B$341.0M$1.8B$1.0BNeeds four quarters10-Q 2026-10-29
Q2 2026
2026-06-30
$1.3B$164.5MNot filed$1.7B$1.0BNeeds four quarters10-Q 2026-07-30
Q1 2026
2026-03-31
Not filed$206.0MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-10-29
Q4 2025
2025-12-31
$1.1B$111.5M$217.7M$1.7B$1.0B$3.7B10-K 2026-02-12
Q3 2025
2025-09-30
$1.2B$292.7M$296.9M$1.5B$1.0B$3.2B10-Q 2026-10-29
Q2 2025
2025-06-30
$773.7M-$72.2M$127.8M$1.1B$1.0B$2.5B10-Q 2026-07-30
Q1 2025
2025-03-31
$594.2M-$18.3M-$118.3M$1.0B$1.0B$2.3B10-Q 2025-05-01
Q4 2024
2024-12-31
$593.2M-$83.8M-$94.7M$966.4M$1.0B$2.2B10-K 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2020-06-05
Latest annual report10-K2026-02-12
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-06

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.8%
1 month-26.3%
3 months-27.3%
Year to date-58.5%
1 year-63.6%
From 52-week high-65.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VTRSViatris Inc.$20.74-0.38%$23.8B
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B
INSMInsmed Incorporated$122.88+1.42%$27.0B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$239.77-0.74%$15.4B
BBIOBridgeBio Pharma Inc.$77.36-1.20%$15.1B
GMABGenmab A/S ADS$51.57+0.39%$32.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier